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causes  of  cancer-related  mortality  worldwide  ( gure  1)     .  The  gastrointes nal  tract 
comprises  of  all  organs  responsible  for  diges on,  including  the  accessory  organs  liver, 
gallbladder,  biliary  tract  and  pancreas.  The most  common  gastrointes nal malignancy  is 
colorectal cancer, which ranks globally third in incidence rate, and even second in mortality 
rate, as  it  solely accounts  for  approximately 1  in  10  cancer-related deaths . Other highly 










































































































Despite  the  length  of  the  small  bowel  within  the  gastrointes nal  tract,  small  bowel 
cancer  is  only  encountered  in  2-3%  of  all  gastrointes nal  cancers. Mul ple  theories  are 
suggested to clarify the rarity of small bowel cancer, including the rapid transit  me of the 
nutri onal elements in  the small bowel, more alkaline environment,  lower bacterial  load 
and the  rapid  turnover of the mucosal area    . Small bowel adenocarcinoma  (SBA)  is the 
most common histologic subtype, accoun ng for almost 40% of the tumours . E ology  is 




Mul ple  risk  factors  for SBA  are  iden  ed,  including  celiac  disease,  Crohn’s  disease  and 




syndrome),  familial  adenomatosis  polyposis  (FAP)  and  Peutz-Jeghers  syndrome7-9. 






loss,  gastrointes nal  bleeding  or  anemia  or  an  acute  clinical  presenta on  with  bowel 









The  incidence  of  appendiceal  cancer  is  also  very  rare,  accoun ng  for  less  than  0.5%  of 
all  gastrointes nal  cancers  and  occurring  in  less  than  2%  of  all  appendectomies       . 
Appendiceal cancer is o en rarely considered or diagnosed preopera vely, as typical and 
speci c symptoms are lacking. General symptoms include vague acute or chronic abdominal 
pain or  symptoms  resembling acute  appendici s            . Also  the  incidence of  diagnosing 








Mucinous  and  signet  ring  cell  adenocarcinomas  belong  to  the  subgroup  of  mucinous 
appendiceal  neoplasms,  which  have  been  of  great  interest,  as  these  tumours  are  the 
leading cause of pseudomyxoma peritonei      . Pseudomyxoma peritonei is a rare peritoneal 











mucinous  appendiceal neoplasms,  and malignant  lesions,  including mucinous  and signet 
ring cell adenocarcinomas  .
                                                                                               
classi ca on,  it  is  possible  that  tumours  of  uncertain  malignant  poten al  with  a  more 
favourable  prognosis  in  both  locoregional  and metasta c  disease, were  falsely  classi ed 
as mucinous  appendiceal  adenocarcinomas and consequently,  incorrectly  in uenced  the 
results of treatment.
                                                                   
Due to  the rarity of  small bowel and appendiceal  tumours, prospec ve cohort studies or 







In  the  area of  rare diseases as  in small bowel  and appendiceal cancer, popula on-based 
research is highly valuable in providing important clinical insights into basic epidemiology, 
prognos c factors and the use and e ects of treatment, as more pa ents over  me could 












The Netherlands  Cancer  Registry  (NCR)  is  a na onwide popula on-based  registry, which 
collects  data  on  all  newly  diagnosed  malignancies  in  the  Netherlands  since  1989.  It  is 
managed by  the Netherlands Comprehensive Cancer Organisa on  (IKNL),  consis ng  of 9 
regions  throughout  the Netherlands, which covers  the en re Dutch popula on of nearly 
17 million inhabitants. Primary source of no  ca on is the Dutch na onwide network and 
registry  of  histo-  and  cytopathology  (PALGA),  accompanied with  data  from  the Na onal 
Registry  of  Hospital  Discharge  Diagnoses  and  radiotherapy  ins tu ons.  Informa on  on 
pa ent  and  tumour  characteris cs,  diagnosis  and  ini al  treatment  is  rou nely  collected 
by  registry  clerks  from  the medical  records.  In  the NCR,  all  primary  tumours  are  staged 
and  registered  according  to  the  Tumour  Node  Metastasis  (TNM)  classi ca on  .  The 
topographical site of the primary tumour and systemic metastases are registered according 
to  the  third  version  of  the  Interna onal  Classi ca on of Disease  for Oncology  (ICD-O)  . 
Informa on of the vital status of pa ents is annually obtained through linkage of the NCR 
with  civil municipal  registries  and  the  central  bureau  for  genealogy,  in which  data  of  all 
deceased and emigrated inhabitants of the Netherlands are collected.
Addi onal data collec on
In  the NCR, extensive data on  the  type and dura on of systemic  therapy of  small bowel 
cancer  is  not  rou nely  collected.  Fortunately,  with   nancial  support  of  the  Catharina 
Research Fund, addi onal data on systemic treatment regimens for pa ents treated with 























appendiceal  cancer,  by  examining  the  epidemiology,  clinical  disease  course,  treatment 
and prognos c  factors of  these  rare  gastrointes nal  cancers.  The main  objec ves  of  the 
described studies in this thesis were:



















In part  III of this  thesis,  the prognos c value of histologic  subtype  in appendiceal cancer 
is  studied,  with  special  a en on  to mucinous  appendiceal  neoplasms,  using  the  recent 
interna onal histopathological classi ca on.  In chapter 6, an overview of the di erences 




management  of  these  tumours  is  provided.  In  chapter  7,  the  prognos c  relevance  of 
histologic  subtype  in  a  subset  of  pa ents with mucinous,  non-mucinous  and  signet  ring 
cell adenocarcinomas in both locoregional disease and metasta c disease of appendiceal 
adenocarcinoma  is  determined.  Chapter  8  evaluated  the  di erences  in  clinical  course of 
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                         All  pa ents  diagnosed  with  small  bowel  adenocarcinoma  in 








twofold  increase  of  duodenal  adenocarcinomas.  Pa ents  with  locoregional  duodenal 
tumours were less likely to undergo surgery (58%), towards 95% of the locoregional jejunal 
and ileal tumours (p < 0.0001). The use of chemotherapy doubled for adjuvant (7 to 15%) 
















intes nal  tumours,  but  the  incidence  is  rising .  Small  bowel  tumours  have  an  unequal 
distribu on in the small bowel. The preferred loca on depends on the histological subtype. 
The  four major  subtypes of  small bowel  tumours  are  adenocarcinomas,  neuroendocrine 
tumours (including carcinoids), gastro-intes nal stromal tumours (GIST) and lymphomas . 
Adenocarcinomas  and  neuroendocrine  tumours  are  the  most  common  subtypes  in  the 
small bowel, both accoun ng for approximately 40% of small bowel tumours3-5.
Pa ents with small bowel adenocarcinomas merely present with non-speci c symptoms, 






Although  the  precise  pathogenesis  of  small  bowel  adenocarcinomas  is  unknown,  most 
available data suggest a carcinoma sequence driven mul step process of speci c gene c 
changes similar to colorectal cancers5-9.
Due  to  the  rarity  of  the  disease,  data  about  small  bowel  adenocarcinomas  are  scarce, 
diverse and contradictory. Therefore we conducted a popula on-based study to establish 







For  this study, data were  retrieved  from the Netherlands Cancer Registry (NCR), which  is 
managed  by  the  Comprehensive  Cancer  Organisa on  the  Netherlands.  The  na onwide 
NCR  covers  nearly  17  million  inhabitants  and  comprises  popula on-based  data  on  all 
newly diagnosed malignancies. Primary source of no  ca on of the NCR is the automated 
na onwide  pathological  archive  (PALGA),  supplemented  with  data  from  the  Na onal 
Registry  of Hospital  Discharge Diagnoses.  Required  informa on on  diagnosis,  treatment, 
pa ent- and tumour characteris cs are rou nely extracted from hospital medical records by 
specially trained registrars opera ng on behalf of the NCR.
Pa ents  were  included  if  they  were  diagnosed  between  1999  and  2013  with  an 
adenocarcinoma  of  the  small  bowel,  according  to  the  third  version  of  the  Interna onal 
Classi ca on of Disease for Oncology (ICD-O) (topography code C17). Tumours were classi ed 
as adenocarcinomas with the following morphology codes: 8140, 8144, 8145, 8210, 8255, 
8260,  8261,  8263,  8480,  8481,  8490,  8560,  8570,  8574.  Pa ents with  adenocarcinomas 
arising  from  a Meckel’s  diver culum,  as well  as  pa ents  with  neuroendocrine  tumours, 
gastrointes nal  stromal  tumours,  lymphomas  or  undi eren ated  tumours  in  the  small 
bowel were excluded from analysis.




















Descrip ve  sta s cs  were  used  to  describe  the  pa ent  and  tumour  characteris cs. 





Age-standardized  incidence  rates  were  calculated  per  100.000  person-years  using  the 
  
Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013
European  standardized  popula on  rate  (ESR)  for  the  respec ve  study  period.  Es mated 





lost  to  follow-up or  s ll alive at  1  January  2014 were censored.  Evalua on of  signi cant 
di erences  of  survival  between  the  subgroups  occurred  by  means  of  a  log-rank  test. 
Mul variable survival analyses, using the cox propor onal hazards model, were carried out 










A  total of  3930 pa ents were  diagnosed with  a  small  bowel  tumour between  1  January 
1999 and 31 December 2013. The most common histological subtype was adenocarcinoma, 
accoun ng for 1775 cases (45%), followed by neuroendocrine tumours (1429 pa ents, 36%) 
and  gastro-intes nal  stromal  tumours  (529 pa ents,  13%).  The  1775 pa ents  diagnosed 
with an adenocarcinoma were enrolled in this study.




The age-standardized  incidence of  small bowel adenocarcinomas  increased  from 0.5  per 
100,000 inhabitants in 1999 to 0.7 per 100,000 inhabitants in 2013 with an es mated annual 
percentage  change  (EAPC)  of  3.7%  (p  <  0.001).  The  increased  incidence  of  small  bowel 
adenocarcinomas  is mainly  caused  by  a  twofold  increase  of  duodenal  adenocarcinomas 
from 233 in 1999-2003 to 478 cases in 2009-2013 (p = 0.013) ( gure 1).
Thirty-three percent of the pa ents had metasta c disease. Over  me the propor on of 
pa ents presen ng with metasta c  disease  increased  from 27%  in  1999-2003  to 38%  in 
2009-2013 (p < 0.0001). Moreover, the percentage of pa ents presen ng with metastases 
in mul ple organs increased as well from 8% in 1999-2003 to 28% in 2009-2013 (p = 0.0003). 
The most  common metasta c  site was  the  liver  (46%),  followed by  the peritoneal cavity 
(29%) and extra regional lymph nodes (12%). Pa ents with metasta c disease arising from 
duodenal origin showed a di erent metasta c pa ern compared to pa ents with primary 











































































































































































































of  the  pa ents  with  duodenal  adenocarcinomas  underwent  surgery,  in  contrast  to 
respec vely 63% and 81% of the pa ents with jejunal and ileal tumours (p < 0.0001). Other 
pallia ve  interven ons,  such  as  a  bilio-diges ve  or  intes nal  bypass,  endoscopic  stent 
placement or celiac plexus block, were performed in 24% of the pa ents with metasta c 
duodenal adenocarcinomas, and respec vely in 5% and 6% of the pa ents with metasta c 
jejunal  and  ileal  tumours.  In  addi on,  14%  of  the  pa ents  with  locoregional  duodenal 
adenocarcinomas received a pallia ve interven on.
Eleven  percent  of  the  pa ents  with  locoregional  disease  received  chemotherapy,  while 
33%  of  the  pa ents  with  metasta c  disease  did.  The  use  of  chemotherapy  increased 
over  me  for pa ents with  locoregional  disease  from 7%  in  1999-2003  to  15%  in  2009-
2013 (p = 0.0001). Of the 91 pa ents with locoregional disease, undergoing both surgical 
resec on  and  chemotherapy,  the  majority  received  the  chemotherapy  in  the  adjuvant 






















































































































The  median  overall  survival  of  pa ents  diagnosed  with  a  small  bowel  adenocarcinoma 
remained stable around 13-14 months, with one and  ve year survival  rates of 53% and 
25%  respec vely.  Pa ents with  locoregional  disease  had a median  overall  survival  of  25 
months  (one and  ve year survival  rates 65% and 36% respec vely). The median overall 
survival of pa ents with locoregional disease increased from 19 months in the  rst period 
to  34 months  in  the  last  period  (p  =  0.0006).  In  pa ents with  locoregional  disease who 
underwent a surgical resec on, an overall survival of 48 months was observed. Whereas 








chemotherapy,  in contrast  to a  3 month median overall  survival  in pa ents who  did not 
receive pallia ve chemotherapy.
Favourable  prognos c  factors,  iden  ed  by  a  separate  mul variable  survival  analysis, 
including pa ents with locoregional disease, were age < 60 years, low tumour stage (stage 






















































































































































































































































































This  popula on-based  study  examined  the  incidence,  treatment  and  overall  survival 
over  me  in pa ents  diagnosed with  a  small  bowel  adenocarcinoma  in  the Netherlands 
between 1999 and 2013 and is one of the  largest conducted  studies  in the  eld of  small 
bowel  adenocarcinomas  so  far.  Our  study  showed  that  the  incidence  of  small  bowel 
adenocarcinomas is rising. Furthermore, we found that the resec on rates in non-metasta c 
small bowel cancer increased and the overall survival in pa ents with locoregional disease 
improved  over   me.  The  overall  survival  of  pa ents  with  metasta c  disease  remained 
stable, despite the increased treatment with pallia ve chemotherapy.













it  can be  explained  by  improved diagnos cs,  resul ng  in  a  reduc on of misclassi ca on 
of  duodenal  adenocarcinomas  as  pancrea c  tumours  and  adenocarcinoma  of  unknown 




can  be  explained  by  stage migra on  caused  by  new  and  improved  diagnos cs,  such  as 
mul detector  row  computed  tomography  scans  (MDCT)  and  magne c  resonance  (MR) 
              .





inten onally cura ve  resec on    . Resec on rates were higher  in  jejunal  and  ileal  tumours 
compared to resec on rates in duodenal tumours, since surgical resec on of upper duodenal 













disease  the twofold  increase  is  remarkable,  since non-observa onal  studies addressing  the 
bene cial e ect of chemotherapy are  lacking. Overman et al found adjuvant chemotherapy 
to be associated with an  improvement of disease  free survival, but not with  improvement 
                      . Recently, a popula on-based study conducted by Ecker et al showed a 
survival bene t of 16 months (42 vs 26 months) for pa ents with stage III tumours treated 
with adjuvant chemotherapy  . We demonstrate  that  in pa ents with  locoregional disease 
















that  pa ents  treated  with  adjuvant  chemotherapy  a er  surgical  resec on  had  signi cant 




<60 years,  tumour stage  I and  II,  surgical  treatment and chemotherapy. These  ndings are 
comparable  to previously determined prognos c  factors                   .  In addi on,  in pa ents 
with  locoregional  disease, duodenal  tumours appeared  to be an adverse prognos c  factor 






with metasta c  disease,  favourable  prognos c  factors  iden  ed  by mul variable  analysis 
included  age  <50  years,  primary  tumour  located  in  the  jejunum,  surgical  treatment  and 
chemotherapy. These prognos c factors are also consistent to previously published data        .
A  limita on  of  our  study  is  that  detailed  informa on  on  performance  status,  nutri onal 




mainly  caused  by  the  rise  of  duodenal  adenocarcinomas.  The  median  overall  survival  of 
pa ents with  locoregional disease  improved signi cantly over  me, which might be due  to 
the increasing use of chemotherapy and the implementa on of centralizing pancrea c cancer 
surgery. However,  the overall  survival of pa ents with metasta c disease  remained stable, 
despite doubling the administra on of pallia ve chemotherapy. Due to the rarity and dismal 
prognosis of this disease,  it  is of importance  to develop  interna onal  studies  to determine 
the op mal treatment for these pa ents. The di erences found in characteris cs and median 
overall  survival  between  pa ents  diagnosed  with  tumours  located  in  the  duodenum  and 
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             The  aim  of  this  popula on-based  study  was  to  provide  insight  into  the 
incidence, risk factors and treatment-related survival of pa ents with peritoneal metastases 
(PM) of small bowel adenocarcinoma (SBA).
          Data  from  the Netherlands  Cancer  Registry were  used.  All  pa ents  diagnosed 
with  SBA  between  2005  and  2014 were  included.  The  in uence  of  pa ent  and  tumour 
characteris cs on  the odds of developing PM was analysed. Subsequently,  for all  further 
analyses, pa ents without  synchronous PM of SBA were excluded. The  log-rank  test and 
Kaplan-Meier  analyses  were  conducted  to  es mate  survival,  and  the  Cox  propor onal 
hazards model was used to evaluate the risk of death.
         Of  the  1428  included  pa ents  diagnosed  with  SBA,  181  (13%)  presented  with 
synchronous  PM.  Synchronous  PM  was  found  in  9%  of  the  duodenal  tumours  and  in 
17% of  the more distal  tumours. Median overall survival of all pa ents with PM was 5.9 
months, whereas survival of both 11 months was observed in pa ents treated with primary 
tumour  resec on or  pallia ve chemotherapy and  32 months  a er  cytoreduc ve surgery 
with hyperthermic intraperitoneal chemotherapy (CRS+HIPEC). Poor prognos c factors for 
survival were age  ≥70 years  (hazard  ra o  [HR] 1.6, 95% con dence  interval  [CI] 1.1-2.2), 
systemic metastases other than PM (HR 2.0, 95% CI 1.4-2.9) and an advanced (HR 1.9, 95% 
CI 1.3-3.0) or unknown T-stage (HR 2.1, 95% CI 1.2-3.5).







One  of  the  most  frequently  a ected  metasta c  sites  in  pa ents  with  small  bowel 
adenocarcinoma (SBA) is the peritoneal cavity, especially in tumours arising from the jejunum 


























the  automated  na onwide  pathological  archive  (PALGA),  supplemented  with  data  from 
the  na onal  registry of hospital  discharge diagnoses.  The NCR comprises  informa on on 
pa ent and tumour characteris cs, diagnosis and treatment, which is  rou nely extracted 
from medical records by specially trained registrars opera ng on behalf of the NCR. In the 
databases  of  the NCR,  the  stage  of  the  primary  tumour  is  established  according  to  the 
tumour-node-metastasis  (TNM)  classi ca on.  In  case  of  missing  pathological  data,  the 
clinical TNM stage is used. The anatomical site of the tumour and metastases are registered 




as metastases  diagnosed  within  3 months  a er  the  ini al  SBA  diagnosis.  Tumours were 
classi ed  as  adenocarcinomas  with  the  following morphology  codes:  8140,  8144,  8145, 
8210,  8255,  8260,  8261,  8263,  8480,  8481,  8490,  8560,  8570  and  8574.  Pa ents  were 
excluded if they were diagnosed with neuro-endocrine tumours, including carcinoids, gastro-
intes nal  stromal  tumours  or  undi eren ated  tumours  or  if  they were newly  diagnosed 
during autopsy.
The  following  treatment modali es were  included  in  the study: pallia ve chemotherapy, 
pallia ve primary tumour  resec on and CRS+HIPEC. Pallia ve chemotherapy was de ned 






Age-standardized  incidence  rates  were  calculated  per  100,000  person-years  using  the 
European  standardized  popula on  rate  for  the  respec ve  study  period.  Di erences  in 










2016.  Survival  was  es mated  with  the  log-rank  test  and  Kaplan-Meier  analyses.  For  all 
possible prognos c factors of overall survival, univariable survival analyses were performed, 
using the Cox propor onal hazards model. If univariable analyses tended towards sta s cal 
signi cance  (p <  0.10),  the  risk of  death  corrected  for  these poten al prognos c  factors 
was subsequently evaluated with mul variable survival analyses. Hazard ra os (HRs) were 
presented with 95% CIs.









most pa ents with PM had a primary  tumour  in  the duodenum (44%). Synchronous PM 
was found in 9% of the pa ents with a primary duodenal tumour, compared with 17% of 













































site.  The  most  commonly  a ected  metasta c  sites  besides  the  peritoneal  cavity  were 

































































































































































































































































































































































Pallia ve  chemotherapy was  administered  in 31% of  the  pa ents with  PM.  It was  twice 
more commonly prescribed to pa ents with a primary non-duodenal  tumour (41%)  than 




Mul variable  logis c  regression  showed  that  higher  odds  ra os  of  developing  PM were 
associated with  a  primary  tumour  distal  to  the  duodenum,  an  advanced  or  unknown  T- 


































































overall  survival  increased  to  11  months  in  pa ents  who  were  treated  with  pallia ve 
chemotherapy, also to 11 months a er surgery of the primary tumour, to 20 months a er 
combined tumour resec on and pallia ve chemotherapy and to 32 months a er CRS+HIPEC 
( gure  2). Over  me,  survival  rates  remained  stable  and  did  not  improve.  Survival  rates 
di ered between the primary tumour loca ons. Pa ents with a primary duodenal tumour 
had a median overall  survival of 3.0 months  (1-year survival  rate 15%),  compared  to 8.6 























Pallia ve surgery + chemo
Time to event (months)
Pa ents at risk (n)                         
Best suppor ve care                    
Pallia ve surgery                      
Pallia ve chemotherapy                    
Pallia ve surgery + 
chemotherapy
                    


















































































































































pa ents  with  SBA  presented  with  synchronous  PM.  PM was most  likely  to  occur  in  the 
small bowel distal to the duodenum (17%). Furthermore, the risk of being diagnosed with 
synchronous PM was higher in pa ents with an advanced or unknown T- and N-stage and 
diagnosis  in  the  period  2010-2014.  Although  median  overall  survival  was  poor,  higher 
survival rates were achieved in the selected group of treated pa ents.






primary  duodenal  tumours and by  the  retroperitoneal  loca on  of  the duodenum, which 
makes  direct  con guous  tumour  spread  less  likely  than  for  tumours  in  intraperitoneally 
located organs, such as the jejunum and the ileum     .




of SBA and PM of CRC, as  iden  ed  in mul variable  logis c  regression, match to a great 
       . However, the percentage of pa ents presen ng with synchronous PM of SBA (13%) 
was almost three  mes higher than the incidence of PM in pa ents with CRC (4-5%)         .
Surgery  with  primary  tumour  resec on was  performed  almost  seven   mes more  o en 












In  the  present study, pallia ve chemotherapy resulted  in a median  overall  survival  of  11 
months, which  is broadly  equivalent  to  the  results  of  earlier  retrospec ve observa onal 
       1, 20-23.  Since  it  is  thought  that  SBA and  CRC  are  similar  in  terms of  carcinogenesis 
and, to some extent, in terms of tumour behaviour, treatment regimens for SBA, especially 
chemotherapeu cal treatment, are extrapolated from CRC      . Various studies have already 




be men oned  that  only  a  small  group  of  highly  selected  pa ents with  probably  limited 













Of  course,  due  to  the  popula on-based  nature  of  our  study,  these  results  should  be 
interpreted with cau on. Unfortunately, the database of the NCR does not provide detailed 
informa on  on  performance  status,  the  extent  of  peritoneal  burden  of  the  disease,  the 




bowel  cancer  to  be  the  lowest  among  all  rare  epithelial  diges ve  cancers  . Meanwhile, 
the present study might provide helpful  insight into PM of SBA, as it showed that certain 










higher median  overall  survival  for  the  selected  group  of  treated  pa ents.  Analogous  to 
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          Data  from  the  Netherlands  Cancer  Registry  of  pa ents  with  metasta c 





prescribed  to  27% of  the  pa ents, mostly  irinotecan-based  (58%). Age 70 years of  older 





             A minority  of  pa ents  were  treated  with  pallia ve  chemotherapy.  First-line 
treatment  consisted  predominantly  of  oxalipla n-based  combina on  chemotherapy, 





Small  bowel  adenocarcinoma  (SBA)  is  a  rare  gastro-intes nal  tumour,  accoun ng  for 










chemotherapeu cal  regimen  has  not  been  de ned.  Pa ents  are  usually  treated  with 
chemotherapeu cal  regimens which  have  been  extrapolated  from  other  gastrointes nal 
cancers. Several studies have demonstrated that combina on chemotherapy consis ng of 
a  uoropyrimidine and pla num compound seems to have  the most bene cial e ect on 
survival, with median overall  survival  rates  ranging between 14 and 18 months                . 
As  a  result,  a  frontline  regimen  of pla num-based  combina on  chemotherapy  has been 
              .
Popula on-based  data, which  re ect daily prac ce and could  be of help  for clinicians  to 
guide  treatment  decisions,  are  currently  lacking.  As  large  prospec ve  clinical  studies 
and  randomised controlled  trials  are virtually  impossible  to conduct  due  to  the  rarity of 







Data  were  obtained  from  the  popula on-based  Netherlands  Cancer  Registry  (NCR).  The 
na onwide NCR  covers  all  nearly  17 million  inhabitants  of  the Netherlands  and  collects 
data on all newly diagnosed malignancies. Primary source of no  ca on is the automated 
na onwide pathological archive (PALGA), accompanied with data from the Na onal Registry 





























agents  into  single-agent  chemotherapy  and  combina on  chemotherapy,  apart  from  the 
  
Pallia ve chemotherapy in synchronous metastases of small bowel adenocarcinoma
addi onal  administra on of  targeted  agents.  Time  to progression  from  the start of  rst- 
to start of  second-line  treatment and second-  to  third-line  treatment was calculated and 
presented in months. Di erences in  me to progression from  rst- to second-line treatment 
between the pa ents receiving single-agent chemotherapy and combina on chemotherapy 
was evaluated with  the Wilcoxon  rank-rum test. Univariable  logis c regression,  including 
the  95%  con dence  interval  (CI),  was  used  to  assess  the  independent  in uence  of  all 
pa ents and clinical characteris cs on  the probability of receiving second-line  treatment. 
If  univariable  analyses  tended  towards  sta s cal  signi cance  (p  <  0.20),  the  probability 





to  follow-up,  emigrated or  s ll  alive  at 1  February  2018 were  censored. Overall  survival 
was es mated with  the  log-rank  test and Kaplan-Meier analyses. Median overall survival 
was presented  in months, with  its  corresponding 95% CIs. The median overall survival of 
the  treated  pa ents  was  compared  to  the  pa ents  only  receiving  best  suppor ve  care. 
Mul variable  cox  propor onal  hazards  regression  analyses  were  performed  to  iden fy 
prognos c  factors  for  overall  survival  in  pa ents  treated  with  pallia ve  chemotherapy. 
Hazard ra os (HRs) were presented with its corresponding 95% CIs.








A  total  of  522  pa ents  were  diagnosed  with  synchronous  metastases  of  small  bowel 
adenocarcinoma between 2007 and 2016, of whom 199 pa ents (38%) received pallia ve 
systemic  treatment.  Mul ple  pa ent-  and  tumour  characteris cs  di ered  between  the 
treated pa ents and  the nontreated  pa ents, as  shown  in  table 1. Pa ents  treated with 
chemotherapy  were  signi cantly  younger,  with  a  median  age  of  63  years,  compared 
with  72  years  in  non-treated pa ents  (p  < 0.0001).  A nonsigni cant  trend was  observed 
with  respect to the primary tumour site, as rela vely more pa ents with a distal tumour 


















capecitabine  (EOX,  n  =  2).  Single-agent  chemotherapy  was  administered  to  20%  of  the 
pa ents, consis ng of  uoropyrimidines in 92% of the cases, mainly capecitabine (n = 32). 








d        General  characteris cs of  the  total pa ent popula on according  to pallia ve chemotherapy 












































































































































































Second-line  systemic  therapy was  received by  only 27% of  the  pa ents  (n  =  50), mostly 
consis ng  of  single-agent  chemotherapy  (58%)  ( gure  1).  Irinotecan  was  administered 

















































Third-line  systemic  therapy  was  received  by  11  pa ents  (6%). Most  third-line  regimens 
were irinotecan-based (n = 8), consis ng of irinotecan monotherapy (n = 3), or combina on 
therapy of a  uoropyrimidine with irinotecan (CAPIRI/FOLFIRI, n = 3) ( gure 1). The targeted 





only  receiving  best  suppor ve  care  had  a median overall  survival  of  3.0 months, with  a 
1-year  survival  rate  of  17%.  In  pa ents  only  receiving   rst-line  treatment,  the  median 
overall survival of pa ents receiving single-agent chemotherapy was 5.6 months, compared 
















































































































































































































































































This  popula on-based  study  aimed  to  provide  insight  into  the  community-based  use 





In   rst-line  treatment,  combina on  chemotherapy  with mainly  an  oxalipla n-containing 
regimen  was  most  o en  prescribed,  analogous  to  gastric  cancer  and  colorectal  cancer 
(CRC), for which  uoropyrimidines and pla num deriva ves are the backbone of pallia ve 
chemotherapy      .  In  the present study, only a  small minority of pa ents with a primary 
duodenal  tumour were classically  treated as gastric cancer with  triplet chemotherapy as 
ECC or EOX, probably as it was historically thought that duodenal tumours more behave like 
gastric cancer, whereas distal tumours share more similari es with CRC .  In recent years, 
several  studies  conducted  on  the  e cacy  of  chemotherapy  in  advanced  gastric  cancer 
















Second-line  therapy was  administered  to  only  about  a  quarter  of  the  pa ents,  which  is 
limited,  even  on  a  popula on-based  level,  as  compared with  pa ents  receiving  second-
line  treatment  in metasta c  disease  of  gastric  cancer  and  CRC25-27.  Possibly,  the  lack  of 




Second-line  treatment  was  mainly  irinotecan-based,  and  40%  of  the  pa ents  received 
irinotecan monotherapy, which  could  have  been  in uenced  by  the  favourable  results  of 
second-line FOLFIRI in establishing disease control a er failure of  rst-line pla num-based 
chemotherapy as reported in a French study  . The prescrip on of irinotecan-based second-





regimens were used           .  In  the  present  study,  the median  age was  slightly  higher  and 
more pa ents had liver metastases compared with other retrospec ve studies. Moreover, 
no pa ents with locally advanced disease were included in the current study, whereas one 
study  did  include  pa ents both with  locally advanced and metasta c disease of  SBA .  In 
comparison to pa ents  in popula on-based studies  treated with pallia ve chemotherapy 
for  other  gastro-intes nal  cancers,  pa ents  with  metasta c  SBA  have  a  worse  median 
overall  survival  than  pa ents with metasta c CRC, whereas  the  survival  of pa ents with 
metasta c SBA and gastric cancer is comparable      .
Pa ents who received  rst-line chemotherapy only had a higher overall survival of 3 to 4 
months  compared  with  pa ents  receiving  best  suppor ve  care. However,  selec on  bias 
should be taken into account as pa ents treated with pallia ve chemotherapy were already 
selected  by  their  trea ng  physician, as  for  instance  re ected  in a  lower median  age. On 
a popula on-based level, a doubling of median overall  survival was observed  in pa ents 
receiving  rst-line combina on chemotherapy.
The  highly  selected  group  of  pa ents  who  were  prescribed  second-line  or  even  third-
line  treatment  had  a median  overall  survival  of  almost  15  and  28 months,  respec vely. 
However, immortal  me bias could have in uenced these results and should be taken into 
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             Data  about  the  use  and  e ec veness  of  targeted  therapy  in  metasta c 







          In   rst-line  treatment,  25  pa ents  (13%)  received  addi onal  targeted  therapy, 
exclusively bevacizumab, and mostly in combina on with CAPOX/FOLFOX (n = 24). A primary 
ileal  tumour  was  the  only  posi ve  predic ve  factor  for  receiving  bevacizumab  in   rst-
line treatment (OR 3.2, 95% CI 1.06-9.93). Median OS for pa ents in whom bevacizumab 
was  added  to   rst-line  chemotherapy  was  9.3  months,  compared  to  9.1  months  with 
chemotherapy only  (p = 0.85). Median OS for pa ents  receiving  rst-line treatment only, 













Small  bowel  adenocarcinoma  (SBA)  is  rarely  encountered,  despite  the  substan al 
mucosal  surface of  the  small  bowel within  the gastro-intes nal  tract . The duodenum  is 









SBA.  As  SBA  and  colorectal  cancer  (CRC)  share mul ple  genomic  altera ons,  treatment 
regimens for SBA are tradi onally extrapolated from CRC  . In metasta c CRC, the targeted 
agents  bevacizumab,  an  an -VEGF-A  (vascular  endothelial  growth  factor-A)  monoclonal 
an body,  and  panitumumab  and  cetuximab,  both  an -EGFR  (epidermal  growth  factor 
receptor)  monoclonal  an bodies,  have  demonstrated  improvement  in  progression-free 
survival  (PFS)12-18. By  analogy,  a  few reports  have  recently  described  the use  of  targeted 
             19-24. Popula on-based data on the use and e ec veness of targeted therapy 
in metasta c SBA are currently lacking. Therefore, a popula on-based study was performed 










na onwide  pathological  archive  (PALGA),  supplemented  with  data  from  the  Na onal 
Registry  of  Hospital  Discharge  Diagnoses.  Specially  trained  registry  clerks  of  the  NCR 






For  this  study,  some  addi onal  data  were  retrospec vely  collected  by  registry  clerks  of 
the NCR on used  systemic  treatment  regimens  for  pa ents  diagnosed with  synchronous 






















First-,  second- and third-line systemic  treatment  regimens were categorized according  to 
the  administered  number  of chemotherapeu cal  agents  into  single-agent  chemotherapy 
and  combina on  chemotherapy.  Di erences  in  pa ent  and  tumour  characteris cs  were 
analysed with a two-sided chi-squared test or Fisher’s exact test in case of small samples. 
Trends  in   me were  evaluated  by means  of  a  Cochran-Armitage  trend  test.  Univariable 
logis c regression, including the 95% con dence interval (CI), was used to determine the 
in uence  of  pa ents  and  clinical  characteris cs  on  the  probability  of  receiving  targeted 
therapy  in   rst-line  treatment.  As  the  number  of  pa ents  were  limited,  mul variable 
regression analyses were not performed.
A propensity score matched sample was generated as the use of popula on-based data could 










































Logis c regression analysis modelling  the  probability  to  receive  bevacizumab  in   rst-line 
treatment revealed only a primary ileal tumour (OR 3.24, 95% CI 1.06-9.93) as compared to 
a primary duodenal tumour as a posi ve predic ve factor in univariable analyses (table 2).
In  second-  or  third-line  treatment,  several  targeted  agents  were  prescribed.  In  the  50 
pa ents  receiving  second-line  systemic  therapy,  10  pa ents  (20%)  received  targeted 
therapy. Bevacizumab was administered to 8 pa ents, whereas an -EGFR monotherapy was 
prescribed to 2 pa ents. In the group of pa ents treated with bevacizumab, it was prescribed 







































































































































































































































































































Pa ents at risk (n)                                   
Chemotherapy only                                          

























































































































The  poten al  bene cial  e ect  of  bevacizumab  to   rst-line  pallia ve  chemotherapy  in 









a  heterogenous  group  of  pa ents with  advanced  SBA,  including  ampullary  tumours  and 
recurrent,  non-cura vely  resected,  unresectable  or metasta c  SBA       .  In  both  reports, 
mul ple chemotherapy  regimens  in  rst- and  second-line  therapy were  used. Moreover, 
bevacizumab was prescribed in  rst-line and for a substan al part beyond  rst-line therapy. 
The  addi onal  administra on  of  bevacizumab  resulted  in  a median  OS  of  21.9 months, 
compared  to  11.4  months  in  the  bevacizumab-untreated  group  of  pa ents.  As  in  both 
studies  all  pa ents  treated  with  bevacizumab  in   rst-  and  second-line  treatment  were 
merged,  immortal  me biases played a major  role  in  these  results and  the  true value of 
bevacizumab in  rst-line treatment could not be established.
The only phase  II-study conducted by Gulha  et al.  inves gated  the bene t of addi onal 
bevacizumab to combina on chemotherapy with CAPOX in 30 pa ents with advanced SBA 
(n  =  23)  and  ampullary  tumours  (n  =  7)  .  Toxicity  in  pa ents  treated with  bevacizumab 
was limited and included hypertension, fa gue and anorexia. No treatment-related deaths 
were reported. The median PFS was 8.7 months and the median OS was 12.9 months. The 
obtained PFS was compared  to  the PFS of  25  pa ents with metasta c  SBA or ampullary 








of  a  guideline  to  treat  SBA  and  the  lack  of  reimbursement  of  costly  targeted  therapy 







Similar  to  the  treatment  of  wild  RAS-type  metasta c  CRC,  an -EGFR  therapy  with 







in   rst-line  treatment  were  not  sta s cally  signi cantly  di erent  in  the  present  study. 
However, as the number of pa ents treated with targeted therapy was low, an obvious non-
signi cant di erence in OS could have been clinically relevant, but such a striking di erence 
was  not  noted.  Although  study  designs  di ered,  the  presented  results  are  in  line  with 
the study of Aydin et al., who  showed non-signi cant di erences  in median OS between 
the  groups  of pa ents  treated with and without  addi onally bevacizumab  a er  rst-line 
treatment only  . Unfortunately, data on PFS were missing in the current study. However, 
in the studies of Aydin et al. and Gulha  et al., no signi cant di erences in PFS were found 





Data  on  mul ple  prognos c  factors  are  lacking,  including  informa on  on,  for  instance, 
extent of  disease, disease  related symptoms, performance status,  comorbidi es  and  the 
  
Addi on of bevacizumab to  rst-line pallia ve chemotherapy in metasta c small bowel adenocarcinoma
presence  of  RAS  or  BRAF  muta ons.  Moreover,  reasons  to  prescribe  chemotherapy  or 
targeted therapy were unknown, dura on of systemic therapy was not well documented for 
all pa ents, and selec on bias could have played a large role. However, as large prospec ve 
studies are hard  to conduct  in  the  eld of  this  rare disease,  the current data are of high 
value into providing insights into the use and e ects of targeted therapy in pa ents with 
metasta c SBA in daily prac ce.
In  conclusion,  taking  into  account  the  limited  number  of  pa ents  receiving   rst-line 
bevacizumab  and  the  unknown  reasons  to  prescribe  addi onal  targeted  therapy,  the 
corresponding survival rates of pa ents treated with and without addi onal bevacizumab 
in  rst-line treatment, might suggest a limited clinical e ect of bevacizumab in addi on to 






1.  Zaanan  A,  Costes  L,  Gauthier  M,  et  al. 
Chemotherapy  of  advanced  small-bowel 
adenocarcinoma:  a  mul center  AGEO  study. 
Ann Oncol. 2010;21:1786-1793.
2.  Aparicio  T,  Zaanan  A,  Svrcek  M,  et  al.  Small 
bowel  adenocarcinoma:  epidemiology,  risk 
factors, diagnosis and treatment. Dig Liver Dis. 
2014;46:97-104.





4.  Dabaja  BS,  Suki  D,  Pro  B,  Bonnen  M,  Ajani 
J.  Adenocarcinoma  of  the  small  bowel: 
presenta on, prognos c factors, and outcome 
of 217 pa ents. Cancer. 2004;101:518-526.
5.  Legue  LM,  Bernards  N,  Gerritse  SL,  et  al. 
Trends  in  incidence,  treatment and survival of 
small  bowel  adenocarcinomas  between  1999 
and  2013:  a  popula on-based  study  in  The 
Netherlands. Acta Oncol. 2016;55:1183-1189.
6.  Overman  MJ,  Kopetz  S,  Wen  S,  et  al. 
Chemotherapy  with  5- uorouracil  and  a 
pla num  compound  improves  outcomes  in 
metasta c  small  bowel  adenocarcinoma. 
Cancer. 2008;113:2038-2045.
7.  Overman MJ, Varadhachary GR, Kopetz S, et al. 
Phase  II  study  of  capecitabine  and  oxalipla n 
for  advanced  adenocarcinoma  of  the  small 
bowel  and  ampulla  of  Vater.  J  Clin  Oncol. 
2009;27:2598-2603.
8.  Tsushima  T,  Taguri  M,  Honma  Y,  et  al. 
Mul center retrospec ve study of 132 pa ents 
with unresectable small bowel adenocarcinoma 




in  advanced  small  bowel  adenocarcinoma. 
An cancer Drugs. 2012;23:561-566.
10.  Zhang L, Wang LY, Deng YM, et al. E cacy of the 
FOLFOX/CAPOX  regimen  for  advanced  small 
bowel  adenocarcinoma:  a  three-center  study 
from China. J buon. 2011;16:689-696.
11.  Aparicio  T,  Svrcek  M,  Zaanan  A,  et  al.  Small 
bowel  adenocarcinoma  phenotyping,  a 
clinicobiological  prognos c  study.  Br  J  Cancer. 
2013;109:3057-3066.
12.  Kim TW, Elme A, Kusic  Z, et al. A phase 3  trial 
evalua ng  panitumumab plus  best  suppor ve 
care vs best suppor ve care in chemorefractory 
wild-type  KRAS  or  RAS  metasta c  colorectal 
cancer. Br J Cancer. 2016;115:1206-1214.
13.  Saltz  LB,  Clarke  S,  Diaz-Rubio  E,  et  al. 
Bevacizumab  in  combina on  with  oxalipla n-
based  chemotherapy  as   rst-line  therapy  in 
metasta c  colorectal  cancer:  a  randomized 
phase  III  study.  J  Clin  Oncol.  2008;26:2013-
2019.
14.  Van Cutsem E, Peeters M, Siena S, et al. Open-
label phase  III  trial of panitumumab plus  best 
suppor ve care compared with best suppor ve 
care  alone  in  pa ents  with  chemotherapy-
refractory  metasta c  colorectal  cancer.  J  Clin 
Oncol. 2007;25:1658-1664.
15.  Peeters  M,  Price  TJ,  Cervantes  A,  et  al. 
Randomized  phase  III  study  of  panitumumab 
with   uorouracil,  leucovorin,  and  irinotecan 
(FOLFIRI)  compared  with  FOLFIRI  alone 
as  second-line  treatment  in  pa ents  with 
metasta c  colorectal  cancer.  J  Clin  Oncol. 
2010;28:4706-4713.
16.  Hurwitz H,  Fehrenbacher  L, Novotny W,  et  al. 
Bevacizumab plus  irinotecan,  uorouracil, and 
leucovorin  for metasta c  colorectal  cancer.   
Engl J Med. 2004;350:2335-2342.
17.  Kabbinavar  FF,  Schulz  J,  McCleod  M,  et  al. 




18.  Van  Cutsem  E,  Kohne  CH,  Lang  I,  et  al. 
Cetuximab  plus  irinotecan,   uorouracil,  and 
leucovorin as  rst-line treatment for metasta c 
                                                    
  
Addi on of bevacizumab to  rst-line pallia ve chemotherapy in metasta c small bowel adenocarcinoma
survival  according  to  tumor  KRAS  and  BRAF 
muta on  status.  J  Clin  Oncol.  2011;29:2011-
2019.
19.  Gulha  P, Raghav K, Shro  RT, et al. Bevacizumab 
combined  with  capecitabine  and  oxalipla n 
in  pa ents with  advanced  adenocarcinoma  of 
the  small bowel or ampulla of vater: A single-
center,  open-label,  phase  2  study.  Cancer. 
2017;123:1011-1017.
20.  Hirao  M,  Komori  M,  Nishida  T,  et  al.  Clinical 
use  of molecular  targeted  agents  for  primary 
small  bowel  adenocarcinoma:  A  mul center 
retrospec ve  cohort  study  by  the  Osaka  Gut 
Forum. Oncol Le . 2017;14:1628-1636.
21.  Takayoshi  K,  Kusaba  H,  Uenomachi  M,  et  al. 
Sugges on  of added value by bevacizumab  to 
chemotherapy  in  pa ents  with  unresectable 
or  recurrent  small  bowel  cancer.  Cancer 
Chemother Pharmacol. 2017;80:333-342.
22.  Aydin D, Sendur MA, Kefeli U, et al. Evalua on 
of  Bevacizumab  in  Advanced  Small  Bowel 
Adenocarcinoma.  Clin  Colorectal  Cancer. 
2017;16:78-83.
23.  Falcone  R,  Roberto  M,  File   M,  Anselmi 
E,  Marche   P.  An   epidermal  growth 
factor  receptor  therapy  in  small  bowel 









based  dosing  of  irinotecan,  oxalipla n,  and 
capecitabine  as   rst-line  therapy  for  pa ents 
with  advanced  small  bowel  adenocarcinoma. 
Cancer. 2017;123:3494-3501.
26.  Overman  MJ,  Pozadzides  J,  Kopetz  S,  et 
al.  Immunophenotype  and  molecular 
























were  used  over  the  years  and  also  owing  to  the  rare  nature  of  these  tumors,  many 

















is  the most common histologic malignant subtype, accoun ng  for more  than half of  the 
     6-8. Other malignant  subtypes of  appendiceal  cancer  include  lymphomas,  sarcomas, 
grade 1 and 2 neuroendocrine tumors (NETs) and goblet cell tumors/carcinomas (previously 
called  goblet  cell  carcinoids)     .  Goblet  cell  tumors  are  a  remarkable  group  of  tumors, 
occurring almost exclusively in  the appendix. Recent  insights have shown that goblet cell 
tumors are lesions composed of several cell types, including neuroendocrine cells, Paneth 
cells  and  goblet  cells.  These  tumors  show  a  con nuum with  adenocarcinomas,  and  the 
prognosis is dependent of the dominant morphologic component of the goblet cell tumor   
  .














Mucinous  appendiceal  neoplasms  are  a  frequently  discussed  item  within  the  group  of 




malignant  poten al,  and malignant  lesions       .  Serrated  polyps  and  tubular,  villous,  and 
tubulovillous  adenomas  all  belong  to  the  group  of  premalignant  lesions.  Meanwhile, 
tumors of uncertain malignant poten al, also known as low-grade appendiceal mucinous 




ring  cell  carcinomas.  The  premalignant  lesions  do  not  have  the  poten al  to  cause  PMP, 
which is not the case for the other 2 categories      .
  D 
A  subgroup  of  mucinous  appendiceal  lesions  can  be  classi ed  as  LAMNs.  Historically, 
cystadenoma  and  mucocele  were  used  as  synonyms  for  LAMN,  but  these  terms  were 
abandoned based on consensus, owing  to  their  incomplete and misleading nature            
  .  The  histologic  criteria  for  LAMN are  summarized  in  table  1.  The most  important  and 
dis nc ve  feature  of  LAMN  is  the  low-grade  cytologic  atypia  without  signs  of  invasive 
in ltra on in the appendiceal wall. In almost all cases of LAMN, there is loss of the normal 
mucosal  architecture  of  the  appendix,  at  least  focally,  with  loss  of  the  lamina  propria 
and  muscularis  mucosa  with  lymphoid  follicle  atrophy  associated  with   brosis  of  the 
submucosa  . LAMNs are the main cause of PMP. These lesions generally do not cause nodal 
or distant extraperitoneal metastases  .
In  case  of  a  suspected  LAMN,  accurate  pathologic  examina on  of  the  total  appendix  is 
essen al, as  some  features are associated with poten al  intraperitoneal  tumour spread, 
which worsens  the  natural  disease  course  and  the  prognosis  of  the  pa ent. Worrisome 
features of LAMN include appendiceal rupture (including micro-perfora on), a background 







with  a  mucinous  adenocarcinoma.  Pa ents  are  generally  young,  with  a  median  age  of 
approximately  53  years,  and  with  a  slightly  female  predominance  (~60%)            .  Among 
all mucinous appendiceal neoplasms without peritoneal spread, it has the most favorable 





















































Appendiceal mucinous  adenocarcinomas  are  de ned  as mucinous  neoplasms  comprised 
of >50% extracellular mucin, with  the presence of  in ltra ve  invasion of  the appendix.    
   According to the PSOGI classi ca on, mucinous adenocarcinomas are classi ed as well, 
moderately,  and  poorly  di eren ated,  although  the  histologic  criteria  for  the  di erent 










intra-abdominal  dissemina on  occurs   rst.  Survival  is  strongly  dependent  of  histological 
                    . Among appendiceal  adenocarcinomas, mucinous  adenocarcinoma has  the 
most favorable prognosis, with a median overall survival of over 60 months. Like colorectal 


















tumor, as morphology can be discordant  in  rare cases. For  instance, pa ents with  LAMN 
may  present  with  high-grade  PMP,  whereas  invasive  adenocarcinomas  could  cause  low-
grade PMP. This discordance may in some cases be explained by sampling error or incorrect 

















































For  pa ents  without  extra-appendiceal  disease,  appendectomy  and  follow-up  is 
recommended.  Right  hemicolectomy  should  not  be  performed,  because  it  provides 
no  survival  bene t  for  pa ents with  LAMNs,  as  these  lesion  usually  do  not  cause  nodal 






(carcinoembryonic  an gen,  cancer  an gen  19.9,  and  cancer  an gen-125)  .  Especially 
in  pa ents with  worrisome  prognos c  signs,  such  as  elevated  tumour markers,  posi ve 
resec on margins  or  the  presence  of  mucin  beyond  the  appendix,  close  and  extended 































In  peritoneal  dissemina on,  CRS+HIPEC  is  recommended  for  all  types  of  PMP,  although 




                                 .  For  example,  in  peritoneal metastases  of  colorectal  origin, 
CRS+HIPEC is usually not performed if PCI ≥20, as radical resec on of the peritoneal tumour 
is  nearly  impossible  and  the  morbidity  caused  by  CRS+HIPEC  outweighs  the  poten al 
minimal bene cial e ect on survival  .
In pa ents with low-grade PMP, CRS+HIPEC should always be considered irrespec ve of the 
PCI.  If  complete  cytoreduc on  could  be achieved,  CRS+HIPEC  is  s ll  a  cura ve op on  in 
pa ents with high peritoneal tumour load         . The great impact of CRS+HIPEC on survival 
in  low-grade PMP  is  re ected  in a  reported median overall  survival of 7.7  to 12.3 years, 
and a 5-year and 10-year survival rate of 84% and 48%, respec vely,  in case of complete 





In  contrast,  the  PCI  may  be  considered  to  select  pa ents  with  high-grade  PMP  for 
CRS+HIPEC,  as  a  high  PCI  is  associated  with  signi cant  poorer  survival.  A er  achieving 
complete  cytoreduc on,  a median  overall  survival  of  2.8  to  5.3  years,  and  a  5-year  and 
10-year survival rate of, respec vely, 48% and 40% are reported                 . However, a er 
incomplete cytoreduc on the 5-year overall survival decreases to only 23%  .
CRS+HIPEC  can  be  considered  in  pa ents  with  high-grade  PMP  with  signet  ring  cells, 






















Pallia ve  systemic  therapy  can  be  considered  in  pa ents  with  irresectable  or  recurrent 
(high-grade)  PMP,  who  are  not  suitable  for  CRS+HIPEC.  Generally  accepted  reasons 
for  surgical  ineligibility  include  short  progression-free  survival  (o en  <1  year  to  prior 
CRS+HIPEC),  residual  disease  a er  prior  CRS+HIPEC,  and  extensive  comorbidi es       . No 
randomized controlled trials have been performed for pallia ve systemic therapy in pa ents 
with PMP. Commonly, chemotherapy regimens by analogy of colorectal cancers are used, 
like   uoropyrimidine-based  regimens,  either   uorouracil/  capecitabine monotherapy,  or 
oxalipla n- or irinotecan-based combina on therapy      . In the series of Choe et al., addi on 
of targeted therapy to pallia ve chemotherapy was used in 50% of the cases, mainly with 



















of  the  higher  grade  tumors  .  However,  the  administra on  of  pallia ve  chemotherapy 






included  in  the  studies were  small  and  selec on  bias  probably  played  a  signi cant  role, 
these  results  favour  the use of pallia ve chemotherapy and targeted  therapy in selected 
pa ents with irresectable or recurrent high-grade PMP.
Pa ents  with  low-grade  PMP  derive  less  to  no  bene t  from  pallia ve  chemotherapy 

























LAMNs and HAMNs, and PMP.  In pa ents with PMP, CRS+HIPEC should be  considered  in 





There seems to be no  indica on  for  standard neo-adjuvant or adjuvant systemic therapy 
in  PMP. However,  it  is  theore cally  possible  that  selected  high-grade  PMP pa ents with 
irresectable disease due to a high degree of tumour burden could bene t from neo-adjuvant 
chemotherapy1, 38-44. On an individual level, the administra on of neo-adjuvant chemotherapy 
could  result  in a  situa on of  resectable peritoneal  disease, a er which CRS+HIPEC could 
be performed. Pallia ve systemic  therapy can be considered  in pa ents with irresectable 










are  largely  derived  of  collected  samples  by  hospitals  and  pathology  archives  .  Data  on 
lesions that were previously assumed to be non-malignant lesions are usually not recorded 
by  cancer  registries.  For  example,  in  the  Netherlands  Cancer  Registry  only  in  case  of 
PMP,  data  on  the  primary  appendiceal  lesions  as  LAMNs  and HAMNs  are  registered.  In 
addi on, due to the new classi ca on of mucinous appendiceal neoplasms, the available 
data of  these  tumours might be contaminated, as  some LAMNs were probably classi ed 
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                          Data  from  the  Netherlands  Cancer  Registry  (NCR)  of  pa ents 
with  primary  appendiceal  adenocarcinomas  with MAC,  AC  and  SRCC  histologic  subtype, 
diagnosed between  2001-2015 were used  (n  =  675).  To  categorize  pa ents  according  to 
the  recent histopathological  classi ca on,  the NCR was  linked with  the Dutch  Pathology 
Registry  (PALGA).  Log-rank  tests  and Kaplan-Meier  analyses were  performed  to es mate 
overall survival (OS), and the cox propor onal hazards model was run to iden fy prognos c 
factors.
          AC  was  the  most  frequently  encountered  histologic  subtype  (50.9%),  followed 





0.005). MAC was associated with higher survival  compared  to AC  (HR 0.48, 95% CI 0.34-
0.69). In subanalyses, MAC was only a posi ve prognos c factor compared to AC in pa ents 
with peritoneal metastases (HR 0.42, 95% CI 0.28-0.62).
             Histologic  subtype  had  no  prognos c  relevance  in  locoregional  or  systemic 
metasta c  disease  in  appendiceal  adenocarcinoma.  In  peritoneal  metastases,  mucinous 






specimens .  The  most  frequently  encountered  malignant  subtype  within  the  group  of 








appendiceal  neoplasms  existed6-10.  Recently,  a  consensus-based  histopathological 
classi ca on  regarding  mucinous  appendiceal  neoplasms  and  pseudomyxoma  peritonei 
(PMP)  was  published  on  behalf  of  the  Peritoneal  Surface  Oncology  Group  Interna onal 
(PSOGI)  . With this classi ca on, appendiceal mucinous neoplasms, including the low-grade 
appendiceal  mucinous  neoplasm  (LAMN),  high-grade  appendiceal  mucinous  neoplasms 
(HAMN) and mucinous appendiceal adenocarcinoma, can be classi ed with interna onally 
corresponding de ni ons, based on well-de ned criteria.
As  universal  and  clear  de ni ons  for mucinous  appendiceal  neoplasms  were  previously 
lacking,  it  could  be  possible  that  prognos cally  favourable  LAMNs  and  HAMNs  were 












of  approximately 17 million  inhabitants.  Primary source of  no  ca on of  the NCR  is  the 
automated na onwide network and registry of histo- and cytopathology in the Netherlands 
(PALGA),  supplemented  with  data  from  the  Na onal  Registry  of  Hospital  Discharge 










were  classi ed  into mucinous  (morphology  codes  8470,  8480  and  8481),  non-mucinous 
(morphology  codes  8140,  8141, 8144,  8145,  8210, 8211,  8255, 8260,  8261,  8262, 8263, 
8440, 8460, 8560, 8570 and 8574) and signet ring cell adenocarcinomas (morphology code 
8490).
As  mul ple  tumour  classi ca ons  of  appendiceal  mucinous  neoplasms  existed  over 









without  con rmed  appendiceal  mucinous  adenocarcinomas  as  origin  and  pa ents with 
























Descrip ve  sta s cs  were  used  to  provide  an  overview  of  the  pa ent  and  tumour 
characteris cs.  Di erences  in  pa ent  and  tumour  characteris cs  were  analysed  with  a 
two-sided chi-square test. Survival  me was de ned as the  me from the date of diagnosis 
to death or last follow-up date for pa ents who were lost to follow-up or s ll  alive at 31 
January  2019.  Survival was  es mated with  the  log-rank  test and  Kaplan-Meier  analyses. 
Mul variable  survival  analyses,  using  the  Cox  propor onal  hazards model,  were  run  to 


















between  2001  and  2015.  A er  revision  of  the  pathological  reports  of  pa ents  ini ally 
diagnosed or  classi ed with mucinous  appendiceal  adenocarcinomas, 264  pa ents were 











n = 355 
Mucinous adenocarcinoma, 
n = 250 
Signet ring cell 
adenocarcinoma, n = 93 
Excluding: 
Failure of primary linkage, n = 29 
Incorrect linkage, n = 4 
Missing informa on, n = 9 
Incorrect or no primary appendiceal 
tumour, n = 32 
Contamina on (appendici s), n = 1 
LAMN, n = 187 
HAMN, n = 4 
Unknown tumour stage, n = 22 
Pa ents with primary appendiceal 
adenocarcinoma, included in the NCR from 
2001-2015 (n = 978) 
Study popula on
Among  the  histologic  subtypes,  signi cant  di erences  were  noted  according  to  stage 


























































































































































































































































































In metasta c  disease, median  overall  survival  di ered  signi cantly  among  the  histologic 
subtypes, being 12.6 months, 27.7 months  and 18.1 months  in metasta c AC, MAC and 
SRCC  respec vely  (p  <  0.005)  ( gure  2). One-year  survival  rates were  53.0%,  69.1%  and 
58.0%  in  AC,  MAC  and  SRCC  respec vely.  Mul variable  survival  analyses  also  revealed 
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In  locoregional disease,  the histologic  subtype was not of prognos c relevance  in overall 
survival. This  nding  is in line with  the  results of Widmann et al., which also showed no 
impact of histologic subtype in survival . However, in metasta c disease, mucinous histologic 
subtype  was  a  prognos c  factor  for  higher  overall  survival,  which was  also  observed  in 
                      . Although  it  should  be  taken  into  considera on  that  the  presence of 
peritoneal dissemina on was the only factor of in uence in metasta c disease, as pa ents 
with a mucinous tumour did not have a signi cant higher overall survival than pa ents with 
a non-mucinous  tumour or SRCC  in  systemic metastases.  These  results are most  likely  a 
re ec on of the biological behaviour of these tumours in peritoneal dissemina on. MAC 
and  SRCC  both  belong  to  the  subgroup  of mucinous  appendiceal  neoplasms, which  are 
                        D       . PMP is a rare clinical disease characterized by progressive 
accumula on of mucinous tumour deposi on and mucinous ascites, which can be classi ed 
based  on  histologic  features  and  its  prognosis  into  four  histologic  subtypes,  including 
acellular PMP, low-grade PMP, high-grade PMP and high-grade PMP with signet ring cells. 
MACs are  the main cause of high-grade PMP, whereas SRCCs can give  rise  to high-grade 
PMP with signet ring cells      . In contrast, non-mucinous tumours cause more frequently 
systemic  metastases  and  classical  non-mucinous  peritoneal  metastases,  which  harbour 
di erent clinical and prognos c features than PMP      .





appendiceal neoplasms and ovarian  cancer can be  challenging,  as mucinous appendiceal 
neoplasms  can mimic  ovarian mucinous  tumors  .  However,  the  observed  rela vely  low 
percentage of ovarian metastases in all histologic subtypes in metasta c disease does not 
explain the female predominance.
Although  the  presented  results were already adjusted  for all available  clinical prognos c 






pa ents with systemic metastases,  currently only systemic pallia ve therapy  is  available. 
Moreover,  pa ents  with  primary  appendiceal  mucinous  tumours,  including  SRCC,  are 





the  present  study.  These  tumours  are  now  recognized  as  a LAMN or HAMN.  Previously, 
these rare tumour types were not clearly de ned, were unknown to some pathologists and 















to AC  and  SRCC  in  pa ents with  peritoneal metastases  of  appendiceal  adenocarcinoma, 
which might be a re ec on of the biological behaviour of PMP compared to classic peritoneal 
metastases  of  non-mucinous  origin.  In  locoregional  disease  and  in  systemic  metasta c 
disease, histologic subtype has no prognos c impact in appendiceal adenocarcinoma. These 
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in  pa ents  undergoing  cytoreduc ve 






















and  subsequently  discussed  in  a  broader  context.  A erwards,  several  methodological 
considera ons  are  discussed  that  should  be  taken  into  account  when  interpre ng  the 










popula on-based  studies  in  SBAs  to  date.  The  study  revealed an  increasing  incidence of 
SBAs, which was mainly caused by an absolute twofold increase of duodenal tumours in the 
latest years, from 233 pa ents in the study period 1999-2003 to 478 pa ents in 2009-2013. 
Moreover,  the percentage of pa ents presen ng with  synchronous metastases  increased 
over  me as well,  from 27%  in 1999-2003  to almost 40% of  the pa ents a decade  later. 













peritoneal  metastases  were  younger,  more  o en  had  a  primary  non-duodenal  tumour 








with  metasta c  small  bowel  cancer.  As  details  on  systemic  treatment  are  not  rou nely 
collected in  the Netherlands Cancer Registry, addi onal data on  rst-,  second- and  third-
line systemic treatment regimens, including details and dura on of the chemotherapeu cal 
and targeted agents, of pa ents diagnosed with metasta c SBA between 2007 and 2016 
































chemotherapy,  the median  overall  survival was  8.5 months,  compared  to 6.4 months  in 
pa ents exclusively  treated with  rst-line chemotherapy, with equal 1-year survival  rates 







to  pseudomyxoma peritonei  (PMP). More  speci cally,  clear  and  universal  de ni ons  for 
mucinous appendiceal neoplasms were established by the development of an interna onal 




Mucinous  appendiceal  neoplasms  can  be  dis nguished  into  3  subgroups,  including  true 
premalignant  lesions  or  adenomas,  tumours of  uncertain malignant  poten al,  known  as 
low-grade mucinous appendiceal neoplasms (LAMNs) and high-grade mucinous appendiceal 
neoplasms  (HAMNs),  and  malignant  lesions,  including  mucinous  and  signet  ring  cell 
adenocarcinomas. PMP is the clinical term for peritoneal disease of mucinous appendiceal 
neoplasms.  It  is  dis nguished  from  usual  non-mucinous  peritoneal  metastases  by  the 
presence of excessive amounts of mucin in the peritoneal cavity. Analogous to the primary 
lesions, PMP  is subdivided into several  categories, based on histologic subtype,  including 
acellular PMP, low-grade PMP, high-grade PMP and high-grade PMP with signet ring cells. 
Poten al  treatment op ons  for the primary lesions, as well as  for  the peritoneal disease 






                  of this  thesis, addi onal data of  the Dutch Pathology Registry  (PALGA) 
was linked with the NCR to create a uniform group of pa ents with mucinous appendiceal 






disease,  histologic  subtype  was  not  a  prognos c  factor  for  overall  survival,  with  5-year 
survival rates for pa ents with non-mucinous adenocarcinoma, mucinous adenocarcinoma 
and  signet  ring  cell  adenocarcinoma  of  60.0%,  60.5%  and  69.6%  respec vely.  However, 
in  metasta c  disease,  mucinous  adenocarcinoma  was  associated  with  higher  survival 
compared to non-mucinous adenocarcinoma (median overall survival 27.7 vs. 12.6 months, 






            described  and  evaluated  the  clinical  disease  course  of  metasta c  mucinous 
appendiceal  neoplasms,  including  LAMNs,  HAMNs  and  mucinous  adenocarcinomas  as 
classi ed  according  to  the  latest  consensus-based  histopathological  classi ca on,  in  a 
veri ed  popula on-based  cohort.  It  was  shown  that  of  the  235  pa ents  registered  as 
metasta c  mucinous  appendiceal  adenocarcinoma  or  PMP,  136  pa ents  (57.9%)  had 












cohort  studies  or  randomized  controlled  trials.  However,  clinicians  are  confronted  with 






sec onal  imaging,  such  as  computed  tomography  (CT)  and magne c  resonance  imaging 
(MRI), tumours in both the small bowel and appendix could be detected more easily, at an 






detected  in  the majority of cases . This enhanced detec on could also partly explain  the 
increased incidence of SBA in the study presented in this thesis.
As presented in this thesis, the increasing incidence rates in SBAs were mainly accountable 
to  the  signi cant  twofold  rise  of  duodenal  adenocarcinomas.  The  increase  in  duodenal 
adenocarcinomas was also observed  in other popula on-based studies, with even an six 
fold  increase  in  both  sexes  in  Sweden  in  the  period  1960-20098-11.  Several  hypotheses 
have been  formulated  for  the di ering  cancer  incidence  rates  in  the duodenum and  the 
more  distal  small  bowel.  First,  the  improved  quality  of  imaging  techniques  could  have 
caused  a  decline  in misclassi ca on  of  duodenal  adenocarcinomas  as  pancrea c  cancer 

















Although metasta c disease  is  frequently encountered  in SBA,  limited data exists on  the 
role  of  pallia ve  systemic  therapy.  Moreover,  no  standard  frontline  regimen  has  been 
de ned due to the lack of randomized trials16-18. In this thesis, only 38% of the pa ents with 
metasta c  disease was  treated with pallia ve systemic  therapy,  even  in  the most  recent 
years. The percentage of treated pa ents is low, compared to colorectal cancer      .
As several molecular altera ons between small bowel cancer and both gastric and colorectal 
cancer  overlap,  pa ents  with metasta c  SBA  are  o en  treated  with  the  same  systemic 












from 3.9 months  to  8.7 months,  in  a  subset  of 80  pa ents,  compared  to  all  other  used 
systemic  regimens  .  In  2010,  Zaanan  et  al.  revealed  a  superiority  of  oxalipla n-based 
combina on  chemotherapy  over  cispla n-based  therapy  in  terms  of  both  progression 
free  survival  (6.9  vs  4.8 months,  p  ≤  0.0001)  and  overall  survival  (17.8  vs  9.3  months, 
p = 0.02)  . Addi onal small phase II studies using doublet oxalipla n-containing pallia ve 
chemotherapy  regimens  showed  promising  results with  response  rates  around  50%  and 
a median  overall  survival of  approximately  15  to  17 months            . As  phase  II  trials  are 
associated  with  several  major  limita ons,  the  implica ons  of  these  kind  of  studies  for 
daily  clinical  prac ce  are  o en  limited.  In  the  present  thesis,  it was  shown  that  in  daily 

















a poten al role  for the  targeted agent bevacizumab     . However,  it should be  taken into 









and  one-year  survival  rates  compared  to  pa ents  treated  with  pallia ve  chemotherapy 
only. All these results might indicate a limited clinical e ect of bevacizumab in addi on to 
pallia ve chemotherapy in daily prac ce on overall survival. However, as 91% of the SBAs 






new  insights  were  gathered  in  appendiceal  cancer,  including  neuroendocrine  tumours, 
goblet  cell  tumours,  mucinous  appendiceal  neoplasms  and  carcinomas40-43.  As  a  result 







classi ca on  for mucinous neoplasms,  including mucinous adenocarcinomas,  resul ng  in 
poten ally incorrect results. Data on the accuracy and clinical relevance of this most recent 
consensus-based  classi ca on  is  largely  lacking.  Studies  included  in  this  thesis  tried  to 
answer  these relevant  research ques ons, and  showed  that in pa ents with appendiceal 
adenocarcinoma, mucinous  histologic  subtype was s ll of prognos c relevance, but  only 
in  pa ents with  peritoneal  dissemina on  (median  overall  survival  31.2  vs.  13.3 months, 









Addi onally,  this  thesis  showed  that  each  subtype  of  mucinous  appendiceal  neoplasm 
























Therefore,  for  chapter  3&4  in  this  thesis,  addi onal  data  was  retrospec vely  collected 
on  systemic  treatment  regimen  for  pa ents  treated with  pallia ve  systemic  therapy  for 
synchronous metastases of  SBA diagnosed between  2007  and 2016  by  registry clerks  of 
the Netherlands Cancer Registry. Moreover, data on several prognos c factors are lacking, 
including  clinical  performance  status,  comorbidi es,  extent  of  the  metasta c  disease, 
disease related symptoms, the serum levels of tumour markers and the muta onal status 
of  the primary tumour such as RAS/BRAF/MSI. Also  informa on regarding metachronous 








external validity, as  it provides  insights  into  the outcomes of unselected pa ents  in daily 




cancer, by  combining  the na onwide clinical data of pa ents with  these  rare diseases  in 





the  treated  and  non-treated  di ered  (chapter  4),  and  even  the  pa ent  characteris cs 







the  treatment, but  rather  the di erences  in pa ent- and  tumour characteris cs. For  this 
reason,  mul variable  regression  models  were  performed  to  determine  the  e ect  of  a 
dependent prognos c  factor,  such as  histologic subtype  (chapter  7), adjusted  for  several 
pa ent  and  tumour  characteris cs.  In  order  to  eliminate  poten al  endogeneity  bias, 
propensity score matching was also used in chapter 5 to compare pa ents with and without 
addi onal  bevacizumab beside  pallia ve  chemotherapy  in metasta c  SBA.  In  this  study, 
propensity scores were determined by means of a  logis c regression model  in which the 
administra on  of  bevacizumab  in   rst-line  treatment  was  the  variable  of  interest,  and 
the  independent variables were  those  factors  that were signi cant  in univariable  logis c 
regression,  in  combina on with  relevant  clinical  features.  Pa ents were matched within 





Several  studies  in  this  thesis may  have  been  exposed  to  immortal  me bias,  as  pa ents 
should  be  alive  to  receive  treatment.  A er  ini al  diagnosis,  a  period  of  immortal   me 
arises un l a  pa ent  receives a  type of  treatment, either surgical or  systemic. Especially 






Stage migra on  should  be  considered when  interpre ng  trends  in  treatment  and  (stage 
speci c)  survival.  Improved diagnos c techniques, especially  in  the area of diseases with 
non-speci c  symptoms  as  small  bowel  and  appendiceal  cancer,  could  have  led  to  an 
earlier  detec on  of  both  the  primary  and  metasta c  disease.  Small  metastases,  which 
were previously invisible on historic imaging techniques, could nowadays be visualized at 













that  elderly  pa ents  (≥70  years)  had  a  lower  chance  to  receive   rst-line  combina on 
chemotherapy and second-line  treatment. Poten ally,  if the number of included pa ents 
was higher,  it  could be hypothe cally possible  that only elderly pa ents ≥75 or 80 years 
were at risk for receiving less  rst-line combina on chemotherapy, and not those pa ents 
with an age of 70-75 years, which might have caused residual confounding. Moreover, as 











In  pa ents  with  synchronous  metastases  of  SBA,  pallia ve  chemotherapy  without  the 
addi on  of  the  targeted  agent  bevacizumab  should  be  considered  in  daily  prac ce.  An 
oxalipla n-based combina on regimen of CAPOX or FOLFOX could be suggested as frontline 
regimen in metasta c SBA. The prescrip on of irinotecan-containing chemotherapy could 
be  a  reasonable  op on  for  second-line  treatment. However, pa ent and  tumour  related 
prognos c factors should be taken into account to determine the best suitable treatment 
for each individual pa ent.











By  centralising  surgical  treatment  in  oesophageal,  gastric  and  pancrea c  cancer,  several 
improvements  in pa ent  related outcomes were seen,  including an  increase  in  resec on 
rates, decline  in postopera ve mortality and a major  increase  in overall  survival61-65. Also 
in pa ents treated with pallia ve systemic therapy in metasta c disease for oesophageal, 
gastric and pancrea c  cancer, a higher survival was observed  in pa ents  treated  in high-
volume  centers66-68.  These  improvements  were  caused  by  the  enhanced  experience  of 
medical  specialists  and  an  improved  infrastructure  for  pa ent  management,  which  are 
various posi ve aspects of centralisa on of care      .










the  pathologic  assessment of  rare  appendiceal  tumours, a  decrease  in misdiagnosis  and 
misclassi ca on is expected, leading to an enhanced pa ent management and poten ally 
improved survival rates.
Notably,  already a part of  the  surgical  treatment  procedures are  centralised  for  pa ents 
with  small  bowel  and  appendiceal  cancer.  For  instance,  for  pa ents  with  locoregional 




pa ents  with  small  bowel  and  appendiceal  cancer  across  the  total  treatment  pathway, 
including all  coopera ng  specialisms of pathologists,  radiologists and medical oncologists 
in mul disciplinary teams, further centralisa on of care for pa ents with small bowel and 
appendiceal cancers would be easy to establish. Hopefully, the further enhanced experience 






As  small  bowel  and  appendiceal  cancer  are  rare,  it  seems  very  hard  to  conduct  large 
prospec ve  observa onal  or  randomized  trials  in  the  future.  E orts  should  be made  to 
improve pa ent care  in pa ents with  these rare diseases by  interna onal coopera on of 
specialised  ter ary medical  centres  through  exchange of  their  exper se  and  knowledge, 
and the crea on of a  large interna onal prospec ve database,  in which extensive pa ent 
baseline  characteris cs,  tumour  characteris cs,  and  details  on  prognos c  factors  and 
treatment would  be  collected. Consequently, pretreatment di erences  between  pa ents 
and the  impact of prognos c  factors  could be be er established,  serving as an entry for 














In  daily  prac ce,  pa ents  with  small  bowel  and  appendiceal  cancers  have  historically 
been  treated  in  a  similar  fashion  as  frequently  encountered  gastrointes nal  cancers, 
mainly  as  colorectal  or  gastric  cancer.  However,  the  ra onale  for  this  extrapola on  is 
not  evidence-based  and  therefore,  this  thesis  aimed  to  provide  insights  into  clinical  and 
pathological  aspects  of  these  two  rare  gastrointes nal  cancers.  It was  shown  that  small 
bowel  and appendiceal  cancer both  have  a  dis nct  clinical  disease course,  compared  to 
other gastrointes nal cancers. Metasta c disease was common in pa ents with SBA, and 
only  a minority was  treated with  pallia ve  systemic  treatment.  An oxalipla n-containing 
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het  meest  voorkomend  is.  Andere  veelvoorkomende  vormen  van  kanker  in  het  maag-
darmkanaal  zijn  lever-,  maag-  en  slokdarmkanker.  In  2018  had  wereldwijd  28%  van  de 
pa ënten  die  gediagnos ceerd  werd  met  kanker,  een  tumor  in  het  maag-darmkanaal. 
Alleen al in Nederland werden in 2018 maar liefst 13.900 pa ënten gediagnos ceerd met 
dikkedarmkanker.
Dunne  darm-  en  appendixkanker  zijn  daarentegen  zeldzame  vormen  van  kanker  in 
het  maag-darmkanaal,  waarmee  jaarlijks  slechts  enkele  honderden  pa ënten  worden 
gediagnos ceerd. Zo werden in Nederland in 2018 slechts 300 pa ënten gediagnos ceerd 
met  dunnedarmkanker  en  200  met  appendixkanker.  Door  het  zeldzame  karakter  van 
deze  tumoren,  is  er weinig onderzoek  verricht  naar deze  tumorsoorten.  In  de dagelijkse 
prak jk worden pa ënten met dunne darm- en appendixkanker daarom vaak beschouwd 
en behandeld als maag- of dikkedarmkanker. Echter is het onduidelijk of dunne darm- en 






kunnen  worden.  Hierdoor  is  het  bestaande  en  uitgevoerde  onderzoek  vaak  gebaseerd 





Het doel  van  dit  proefschri   is  om  inzicht  te  verkrijgen  in  de klinische  en  pathologische 
aspecten van dunne darm- en appendixkanker, door het bestuderen van de epidemiologie 
(de leer van het optreden en de verspreiding van ziekten in de bevolking en de kennis van 
factoren die hierop van  invloed  zijn), het  ziektebeloop, de behandeling en prognos sche 
factoren  van  deze  twee  zeldzame  tumoren  in  het  maag-darmkanaal.  De  belangrijkste 
doelstellingen van dit proefschri  zijn:
   Inzicht geven in de epidemiologie van locoregionale (niet uitgezaaide) en gemetastaseerde 
(uitgezaaide)  dunnedarmkanker,  door  het  bestuderen  van  de  inciden e  (het  aantal 
nieuwe pa ënten met  een  ziekte  per  jaar),  behandeling  en  overleving  van  pa ënten 
over de  jd (deel I).
   Evalueren  van  het  gebruik  en  de  e ecten  van  pallia eve  systemische  therapie 
(behandeling met chemotherapie of doelgerichte therapie, die niet meer gericht is op 
genezing) bij pa ënten met uitgezaaide dunnedarmkanker (deel II).





                  wordt  de  inciden e,  behandeling  en  overleving  van  pa ënten  over   jd 
met  locoregionale  en  gemetastaseerde  dunnedarmkanker  (subtype:  adenocarcinoom) 





de meeste  pa ënten  uitzaaiingen  in  de  lever  (46%)  en  het  peritoneum  (buikvlies,  29%), 
al was dit a ankelijk van de  primaire  loca e van de  tumor. Pa ënten met een  tumor  in 
de twaalfvingerige darm hadden vaker leveruitzaaiingen (54%), terwijl pa ënten met een 
tumor verderop in de dunne darm vaker buikvliesuitzaaiingen (44%) hadden. Ondanks het 
toenemende  gebruik  van  pallia eve  chemotherapie,  hadden  pa ënten  met  uitgezaaide 
ziekte een overleving van ongeveer 4-5 maanden.






waren  pa ënten  met  buikvliesuitzaaiingen  vaak  jonger  en  hadden  ze  vaker  een  tumor 
verderop in de dunne darm (na de twaalfvingerige darm). De overleving van pa ënten die 
geen tumorgerichte behandeling kregen, was slechts 2.5 maand. Pa ënten die behandeld 











72  jaar).  Als  aanvangstherapie  ontving  80%  van  de  pa ënten  combina echemotherapie 
(meer dan 1 middel), voornamelijk CAPOX of FOLFOX. Pa ënten die behandeld werden met 
monotherapie  (1 middel)  kregen  in 86% van de gevallen capecitabine. Oudere pa ënten 
(70+)  werden  vaker  behandeld  met  monotherapie  dan  met  combina echemotherapie. 
Tweedelijnsbehandeling  (de  opvolgende  behandeling  na  aanvangstherapie) werd  slechts 




en  geen  opvolgende  lijn  behandeling  hadden  gekregen,  hadden  een  overleving  van  7.0 
maanden na combina echemotherapie en 5.6 maanden na monotherapie.
                 wordt  vervolgens  het  gebruik  en  e ect  van  doelgerichte  therapie,  naast 
het  gebruik  van  pallia eve  chemotherapie,  geëvalueerd  bij  pa ënten  met  uitgezaaide 
dunnedarmkanker. Hierbij werd  gevonden  dat  slechts  13%  van  de pa ënten  bij aanvang 
behandeld  werd  met  aanvullende  doelgerichte  therapie,  naast  chemotherapie.  Hierbij 
werd alleen het doelgerichte middel bevacizumab voorgeschreven. In 96% van de gevallen 
was  dit  in  combina e met  combina echemotherapie met  CAPOX  of  FOLFOX.  Pa ënten 
met een ileumtumor (laatste stuk dunne darm grenzend aan de dikke darm) kregen vaker 
bevacizumab voorgeschreven dan pa ënten met dunnedarmkanker in een ander deel van 




wel  behandeld  was  met  bevacizumab  in  combina e  met  chemotherapie.  Als  wederom 
weer  gekeken werd  naar  pa ënten  die  alleen  behandeld  waren  met  aanvangstherapie, 
zonder  opvolgende  lijn  behandeling,  was  de  overleving  6.8 maanden  voor  pa ënten  na 







appendixtumoren  te  kunnen  classi ceren.  In                worden  de  verschillende 
histologische subtypes bij pa ënten met mucineuze appendixtumoren uitgediept aan de 












met  zegelringcellen.  Laaggradig PMP wordt  in  de meeste gevallen  veroorzaakt  door een 
primaire LAMN, hooggradig PMP door een mucineus adenocarcinoom en hooggradig PMP 
met zegelringcellen door een zegelringcel adenocarcinoom.
                         wordt  verder  ingegaan  op  mucineuze  appendixtumoren,  waarbij 
gebruik  gemaakt  is  van  aanvullende  data  van  het  Pathologisch-Anatomisch  Landelijk 
Geautoma seerd  Archief  (PALGA;  de  landelijke  Nederlandse  pathologiedatabase).  In 
             wordt  de  prognos sche waarde  van  histologisch  subtype  bij  pa ënten met 
appendixtumoren  beschreven,  waarbij  gekeken  is  naar  pa ënten  met  mucineuze,  niet-
mucineuze (niet slijmvormende) en zegelringcel adenocarcinomen in de periode 2001 tot 
2015. Hierbij werd gevonden dat bij niet uitgezaaide ziekte, histologisch subtype niet van 
prognos sche waarde was  op  de  overleving  van  pa ënten.  In  het  geval  van  uitgezaaide 

























vaak  behandeld  op  eenzelfde manier  als  andere  veelvoorkomende maag-darmtumoren, 
zoals  maag-  en  dikkedarmkanker.  De  onderbouwing  hiervoor  ontbreekt  echter 
grotendeels.  Dit  proefschri   verscha   inzicht  in  de  klinische  en  pathologische  aspecten 
van  dunne  darm-  en  appendixkanker,  door  het  bestuderen  van  de  epidemiologie,  het 
ziektebeloop, de behandeling en prognos sche factoren bij deze twee zeldzame tumoren 
in  het maag-darmkanaal.  Dit  proefschri   laat  zien  dat  dunne  darm-  en  appendixkanker 
unieke  kankersoorten  zijn,  met  ieder  een  zeer  verschillend  ziektebeloop.  Pa ënten met 
dunnedarmkanker werden  vaak al bij diagnose gediagnos ceerd met uitgezaaide  kanker, 




middel  bevacizumab.  Bij  pa ënten  met  appendixkanker  is  histologisch  subtype  van 
prognos sche waarde, voornamelijk in het geval van naar het buikvlies uitgezaaide ziekte. 
Derhalve is het van belang om de weefsels van pa ënten met mucineuze appendixtumoren 
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